1 2	Metabolic alkalosis and mortality in COVID-19
3	Dr Zhifeng Jiang (Correspondence author) ,Xiaogan Hospital Affiliated to Wuhan
4	University of Science and Technology; No.6, Square street, Xiaonan District, Xiaogan
5	City, Hubei Province, China. email addresses : xjiang292@sina.com.
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	

24 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 Abstract

26 Background

As a new infectious disease affecting the world, COVID-19 has caused a huge impact on countries around the world. At present, its specific pathophysiological mechanism has not been fully clarified. We found in the analysis of the arterial blood gas data of critically ill patients that the incidence of metabolic alkalosis in such patients is high.

31 Method

We retrospectively analyzed the arterial blood gas analysis results of a total of 16 critically ill patients in the intensive ICU area of Xiaogan Central Hospital and 42 severe patients in the intensive isolation ward, and analyzed metabolic acidosis and respiratory acidosis. Metabolic alkalosis and respiratory alkalosis, and the relationship between metabolic alkalosis and death.

37 **Result**

Among the 16 critically ill patients, the incidence of metabolic alkalosis was 100%, while the incidence of metabolic alkalosis in severe patients was 50%; the mortality rate in critically ill patients was 81.3%, and 21.4% in severe patients ; The mortality of all patients with metabolic alkalosis is 95.5%, and 4.5% in without metabolic alkalosis.

43 **Conclusion**

The incidence of metabolic alkalosis in critically ill COVID-19 patients is high, and itis associated with high mortality.

46 Key words :COVID-19, Metabolic alkalosis, mortality

47 Introduction

COVID-19 has now swept the world, causing huge challenges and disasters to the 48 global health system. At present, its detailed pathophysiological mechanism has not 49 vet been fully clarified. The current research involves direct virus attack, humoral and 50 cellular immunity, and nervous system damage. Endocrine disorders, respiratory and 51 52 circulatory disorders, coagulation dysfunction and other aspects(1). There is still a lack of effective treatments. Critically ill patients still have a high mortality rate. Early 53 data from Wuhan showed that the mortality rate of severely ill patients with 54 55 COVID-19 was 62%, and the mortality rate of patients requiring mechanical ventilation was 81%(2). This manuscript analyzes the blood gas analysis data and 56 deaths of critically ill patients in Xiaogan Central Hospital in March 2020, and finds 57 58 that the incidence of metabolic alkalosis in critically ill patients is very high, and it is accompanied by a higher mortality rate. 59

60 Method

Follow the Helsinki Declaration as revised in 2013, we analyzed 44 patients in the 61 intensive isolation ward of Xiaogan Central Hospital, with an average age of 53 years, 62 27 males and 15 females. There was no history of Gitelman and Bartter syndrome in 63 all patients, and exclude 2 cases of primary aldosteronism in patients. According to 64 the diagnostic criteria of the fifth edition of China's new coronavirus diagnosis and 65 treatment guidelines (meet any of the following 1. Respiratory distress, RR>30 66 beats/min; 2. In the resting state, the oxygen saturation is <93%; 3. Arterial partial 67 pressure of oxygen (PaO2)/inhaled oxygen concentration (FiO2) <300mmHg). All 42 68

patients were diagnosed as severe. Analyzing the arterial blood gas analysis data and death data of 42 patients; According to the same diagnostic criteria, we analyzed the arterial blood gas analysis data and death data of a total of 16 critically ill patients, 11 were males and 5 were females, with an average age of 67 years. (meet one of the following conditions:1. Respiratory failure occurs and mechanical ventilation is required; 2.Shock;3. combined with other organ failure, ICU monitoring and

treatment is required) in the intensive ICU of our hospital.

75

Analyze the arterial blood gas data of all patients, select the highest bicarbonate value 76 77 as the statistical data, including carbon dioxide partial pressure (PaCO2), oxygen partial pressure (PaO2), bicarbonate (HCO3-), alkali excess (BE), serum potassium 78 and calculate acid-base imbalance types, including metabolic acidosis, respiratory 79 80 acidosis, metabolic alkalosis, respiratory alkalosis, respiratory acidosis combined with metabolic alkalosis, and analyze the mortality of critical and severe patients, at the 81 same time, compare the mortality of patients with metabolic alkalosis and 82 non-metabolic alkalosis. In addition, respiratory acidosis combined with metabolic 83 alkalosis and metabolic alkalosis were combined as metabolic alkalosis, and the 84 incidence of alkalosis and mortality were compared again simultaneously compare 85 the serum potassium of the two groups of patients. Use spss25.0 statistical software to 86 analyze this data. The basic description of the count data is expressed by frequency 87 and composition ratio, and the analysis of the difference between the two groups of 88 count data uses the χ^2 test, t test is used for measurement data, P<0.05 indicates that 89 the difference is statistically significant. 90

91 **Result**

There were 10 cases of acid-respiratory and metabolic alkalosis in critically ill 92 patients, with an incidence rate of 62.5%, and 11 cases of acid-respiratory and 93 metabolic alkalosis in severe patients, with an incidence of 26.2%, χ^2 was 6.613, 94 P=0.010, there was a statistical difference in the incidence of the two groups. The 95 incidence of acid and alkali substitution in critical cases was significantly higher than 96 that in severe cases. There were 6 cases of metabolic alkalosis alone in critically ill 97 patients with an incidence rate of 37.5%, and 10 cases of metabolic alkalosis in severe 98 patients with an incidence rate of 23.8%, χ^2 was 1.087, P=0.297, there was no 99 statistical difference in the occurrence of metabolic alkalosis between the two groups. 100 However, when the number of cases of respiratory acidosis combined with metabolic 101 102 alkalosis and metabolic alkalosis are combined, the incidence of metabolic alkalosis in critical cases is 100%, and the incidence of metabolic alkalosis in severe patients is 103 50%.(Table 1) 104

Comparing the two groups of patients with simple metabolic alkalosis and respiratory 105 acidosis combined with metabolic alkalosis, it was found that among the dead patients, 106 14 cases of respiratory acidosis combined with metabolic alkalosis accounted for 107 63.6%, there are no respiratory acidosis combined with metabolic alkalosis in 8 case, 108 accounting for 3.4%, with a χ^2 of 11.546 and a P value of 0.001; When analyzing the 109 death of patients with simple metabolic alkalosis, it was found that the death had 110 nothing to do with simple metabolic alkalosis, χ^2 was 0.318, P=0.573, when 111 respiratory acidosis combined with metabolic alkalosis and metabolic alkalosis are 112

combined as the number of cases of metabolic alkalosis, a total of 21 deaths, a ratio of 95.5%, and no metabolic alkalosis is 1 death, accounting for 4.5%, the χ^2 was 15.383, and the P value is 0.000, the incidence of metabolic alkalosis is higher in deceased patients; Serum potassium in the critically ill was 3.41+-0.4mmol/L, and

3.68±0.46mmol/l in severe group, critically ill patients have lower blood potassium
than severe patients (Table2).

119 **Discusstion**

COVID-19 patients experience a variety of acid-base balance disorders during their 120 121 course of disease. The assessment and research on the acid-base balance disorders of COVID-19 patients is still insufficient (3), which is different from our conventional 122 understanding-the main target of damage due to COVID-19 The organ is the lung, 123 124 which may cause respiratory acid-base balance disorders. A retrospective blood gas analysis study showed that the most common acid-base balance disorder in patients 125 with COVID-19 is keratogenic alkalosis(3). A report from South Africa has been 126 shown that metabolic alkalosis is more common in COVID-19 virus-positive patients 127 (4). Our research also shows that metabolic alkalosis is the most common acid-base 128 balance disorder in such patients. 129

The causes of metabolic alkalosis include extrarenal factors and renal factors. extrarenal factors include gastric acid loss, such as vomiting, nasogastric tube drainage, and loss of intestinal acid, such as villous adenoma, congenital celiac disease, excessive oral or parenteral intake of bicarbonate; Kidney factors such as high mineralocorticoid activity and high distal sodium delivery, persistent

mineralocorticoid overdose, potassium deficiency(5). Our severe patients do not have 135 the above-mentioned extrarenal factors, unintentional excessive intake of bicarbonate, 136 137 and a small number of critically ill patients have nasogastric tube drainage, so such a high incidence of metabolic alkalosis needs to consider renal factors. 138 The destruction of cells entering the viral receptor, angiotensin-converting enzyme 139 (ACE-2) II, is considered to be one of the main causes of human pathogenicity of 140 SARS-CoV-2. ACE-2 is widely expressed in renal tubular epithelial cells, vascular 141 components and glomerular epithelium (6). Once the SARS-CoV-2 bound ACE-2 is 142 internalised by the cell, ACE2 is markedly downregulated (7). Theoretically, it 143 should lead to the excessive renin-angiotensin-aldosterone system mediated by excess 144 angiotensin II activate (8, 9). 145

146 In addition, studies have reported widespread hypokalemia in COVID-19 patients.

The publication of a preprinted retrospective chinese study initially sparked interest in 147 hypokalemia, which is a potentially common biochemical disorder in SARS-CoV-2 148 infection, and serum potassium was present in 108 of 175 patients <3.5 mmol/l (62%), 149 only 10 patients had serum K > 4.0 mmol/l. Of these patients, 22% had severe 150 hypokalemia (serum potassium <3.0 mmol/l). In total, 11% of all patients and 28% of 151 patients with severe hypokalemia showed metabolic alkalosis (pH> 7.45), compared 152 with 4% of patients with normal potassium. (10) However, the largest SARS-CoV-2 153 case series to date (including 1,099 patients) did not show any significant difference 154 in serum potassium between mild and severe patients, in this cohort, serum potassium 155 was mostly reported as normal (11). Our research shows that there is no significant 156

difference in serum potassium between critically ill and critically ill patients, but bothare at a low level.

Virtually all forms of metabolic alkalosis are sustained by enhanced collecting duct hydrogen ion secretion, induced by stimulation of sodium uptake through the epithelial sodium channel(12). In the renal collecting duct, mineralocorticoids drive Na+ reabsorption, K+ secretion, and H+ secretion through coordinated actions on apical and basolateral transporters(13).

Therefore, we speculate that SARS-CoV-2 uses ACE-2 as its cell receptor, leading to 164 165 ACE2 degradation and ACE/ACE-2 imbalance, increasing Ang II levels, inducing the release of aldosterone and increasing mineralocorticoids, which in turn leads to 166 blood potassium reduction and metabolic alkalosis. In addition, patients with 167 168 COVID-19 often have small airway ventilatory disorders, complicated by respiratory acid. In patients with acute respiratory acidosis, PaCO2 increases by 10 mmHg, 169 HCO3- increases by 1 mmol/l, while in chronic respiratory acidosis patients, PaCO2 170 increases by 1 mmol/l. In patients with acidosis, for every 10 mmHg increase in 171 PaCO2, HCO3- increases by 4 mmol/l. In the post-hypercapnia state, respiratory 172 acidosis improves (such as receiving mechanical ventilation), but HCO3- continues 173 to rise, leading to metabolic alkalosis(14). In addition, in this study, the patient intake 174 data cannot be counted in detail. Whether there is insufficient intake and aggravation 175 of alkalosis needs further evaluation. 176

Metabolic alkalosis can lead to a series of serious consequences. First, elevated pH
leads to respiratory depression, and alkalosis is a powerful vasoconstrictor. A large

number of studies have shown that increase in pH leads to a decrease in perfusion ofthe heart, brain and peripheral circulation(15).

181 Metabolic alkalosis is the most common acid-base disorder in hospitalized patients, and it is associated with increased mortality. An earlier study by Wilson et al. in 1415 182 critically ill surgical patients showed that 177 (12%) developed severe metabolic 183 alkalosis defined as arterial pH >7.54 (15). More severe metabolic alkalosis was 184 associated with higher mortality. Mortality was 41% in patients with pH 7.55-7.56, 47% 185 in patients with pH 7.57-7.59, 65% in patients with pH 7.60-7.64, and 80% in patients 186 187 with pH 7.65-7.70. A prospective study by Anderson et al. in a group of 409 medical and surgical patients showed that mortality was 48.5% in patients with pH >7.60 (16). 188 This study shows that among critically ill patients, the incidence of metabolic 189 190 alkalosis is 100% and the mortality rate is 81.25%, and the mortality rate of severe and critically ill patients with metabolic alkalosis is as high as 95.5%. 191 However, the amount of data in this study is still small, and there may be therapeutic 192 193 factors that interfere with the acid-base balance during the treatment of patients. If a

large sample, a more detailed stratified design, and dynamic detection of patient
 ACE-2/renin-angiotensin-aldosterone levels can reveal more secrets.

In conclusion, in severe and critically ill patients, the proportion of metabolic alkalosis has increased significantly, and the mortality rate in patients with metabolic alkalosis has increased significantly. In COVID-19 patients, we need to pay attention to kidney damage as much as the lungs.

200

- **Conflicts of interest:** The authors declare that they have no competing interests.
- **Funding:** There are no funding.
- 204 Consent statement: Written consent was obtained from the patient/ guardian.
- 205 Acknowledgments: We Thank Dr.Aiqiao Feng, Dr. Zhibin Xie, Dr Tao Li, Dr.Sai
- 206 Xie,and Dr. Xiaofei Hu for contributions to the diagnosis and treatment of patients
- and writing suggestions.

<u>___</u>

235 **Reference**

- 236 1 Polak SB, Van Gool IC, Cohen D, et al. A systematic review of pathological
- findings in COVID-19: a pathophysiological timeline and possible mechanisms
- of disease progression. Mod Pathol. 2020 Jun 22 : 1–11.
- 239 2 Yang X, Yu Y, Xu J. Clinical course and outcomes of critically ill patients with
- 240 SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective,
- observational study. Lancet Respir Med. 2020.
- 242 3 Alfano G, Fontana F, Mori G, et al. Acid base disorders in patients
- 243 with COVID-19. Int Urol Nephrol. 2021 Jun 11 : 1–6.
- 4 J Rood, R Davids, A Le Roux, et al. A Parker, B W Allwood, H W Prozesky, C
- F N Koegelenberg, J J Taljaard. Metabolic alkalosis in hospitalised COVID-19

246 patients: A window to the pathogenesis? S Afr Med J. 2020 Oct

- 247 1;110(11):13109.
- 248 5 Palmer BF, Alpern RJ. Metabolic Alkalosis. J Am Soc Nephrol.
- 249 1997 ;Sep;8(9):1462-9.
- 250 6 Owen Wiese, Annalise E, Zemlin, et al. Molecules in pathogenesis: angiotensin
- converting enzyme 2 (ACE2).J Clin Pathol. 2020 Aug : jclinpath-2020-206954.
- 252 7 Morag J Young, Colin D Clyne, Karen E Chapman. Endocrine aspects of ACE2
- regulation: RAAS, steroid hormones and SARS-CoV-2. J Endocrinol. 2020
 Nov;247(2):R45-R62.
- Alfano G, Guaraldi G, Fontana F, et al. The role of the renin-angiotensin system
 in severe acute respiratory syndrome-CoV-2 infection. Blood Purif.
 2021;50(2):263-267.

- 258 9 Ni W, Yang X, Yang D, et al. Role of angiotensin-converting enzyme 2 (ACE2)
- 259 in COVID-19. Crit Care. 2020;24:422.
- 260 10 Dong Chen, Xiaokun Li, Qifa Song, et al. Assessment of Hypokalemia and
- 261 Clinical Characteristics in Patients With Coronavirus Disease 2019 in Wenzhou,
- 262 China JAMA Netw Open. 2020 Jun; 3(6): e2011122.
- 263 11 Guan WJ, Ni ZY, Hu Y, et al. : Clinical Characteristics of Coronavirus Disease
- 264 2019 in China. N Engl J Med. 2020;382:1708–1720.
- 265 12 F John Gennari. Pathophysiology of metabolic alkalosis: a new classification
- based on the centrality of stimulated collecting duct ion transport. Am J Kidney
- 267 Dis. 2011 Oct;58(4):626-36.
- 268 13 Megan M Greenlee, I Jeanette Lynch, Michelle L Gumz, et al. Mineralocorticoids
- 269 Stimulate the Activity and Expression of Renal H+,K+-ATPases. J Am Soc
- 270 Nephrol. 2011 Jan; 22(1): 49–58.
- 14 Banga A, Khilnani GC. Post-hypercapnic alkalosis is associated with ventilator
 dependence and increased ICU stay. COPD J Chronic Obstr Pulm
- 273 Dis. 2009;6:437–440.
- Wilson RF, Gibson D, Percinel A, et al. Severe alkalosis in critically ill surgical
 patients. Arch Surg. 1972;105:193–203.
- Anderson LE, Henrich WL. Alkalemia-associated morbidity and mortality in
 medical and surgical patients. South Med J. 1987; 80:729–733.
- 278

279

group	case	critically ill	Severe	χ²/t	Р
AC &MA				6.613	0.010
Yes	21	10(62.5%)	11(26.2%)		
No	37	6(37.5%)	31(73.8%)		
Metabolic					
alkalosis				1.087	0.297
Yes	16	6(37.5%)	10(23.8%)		
No	42	10(62.5%)	32(76.2%)		
Death				17.611	0.000
Yes	22	13(81.3%)	9(21.4%)		
		3(18.8%)	33(78.6%)		
No	36				
Combined					
metabolic					
alkalosis				12.541	0.000
Yes	21	16(100.0%)	21(50.0%)		
	24	0(0.0%)	21(50.0%)		
	21				
No					
No Serum					
	-	3.41±0.40	3.68±0.46	-2.026	0.048
Serum potassium	- parison of	3.41 ± 0.40 the incidence o			
Serum potassium Table1 Com	-		f acid-base bala	nce disorders	in critically
Serum potassium Table1 Com	-	the incidence o	f acid-base bala	nce disorders	in critically
Serum potassium Table1 Com and critically alkalosis)	-	the incidence o	f acid-base bala	nce disorders	in critically
Serum potassium Table1 Com and critically	-	the incidence o	f acid-base bala	nce disorders	in critically
Serum potassium Table1 Com and critically alkalosis)	-	the incidence o	f acid-base bala	nce disorders	in critically
Serum potassium Table1 Com and critically alkalosis)	-	the incidence o	f acid-base bala	nce disorders	in critically
Serum potassium Table1 Com and critically alkalosis)	-	the incidence o	f acid-base bala	nce disorders	in critically
Serum potassium Table1 Com and critically alkalosis)	-	the incidence o	f acid-base bala	nce disorders	in critically
Serum potassium Table1 Com and critically alkalosis)	-	the incidence o	f acid-base bala	nce disorders	in critically
Serum potassium Table1 Com and critically alkalosis)	-	the incidence o	f acid-base bala	nce disorders	in critically
Serum potassium Table1 Com and critically alkalosis)	-	the incidence o	f acid-base bala	nce disorders	in critically
Serum potassium Table1 Com and critically alkalosis)	-	the incidence o	f acid-base bala	nce disorders	in critically
Serum potassium Table1 Com and critically alkalosis)	-	the incidence o	f acid-base bala	nce disorders	in critically
Serum potassium Table1 Com and critically alkalosis)	-	the incidence o	f acid-base bala	nce disorders	in critically
Serum potassium Table1 Com and critically alkalosis)	-	the incidence o	f acid-base bala	nce disorders	in critically
Serum potassium Table1 Com and critically alkalosis)	-	the incidence o	f acid-base bala	nce disorders	in critically
Serum potassium Table1 Com and critically alkalosis)	-	the incidence o	f acid-base bala	nce disorders	in critically

group	case	no death	death	χ^2	Р
AC &MA				11.546	0.001
Yes	21	7(19.4%)	14(63.6%)		
No	37	29(80.6%)	8(36.4%)		
metabolic					
alkalosis				0.318	0.573
Yes	16	9(25.0%)	7(31.8%)		
No	42	27(75.0%)	15(68.2%)		
Combined					
metabolic				15 292	0.000
alkalosis				15.383	0.000
Yes	37	16(44.4%)	21(95.5%)		
No	21	20(55.6%)	1(4.5%)		

Table 2 Number of deaths in acid-base imbalance.(AC &MA: Respiratory acidosis combined with metabolic alkalosis)

296

293